Logo

Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

Share this
Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

Shots:

  • Marinomed to receive $2M up front & is eligible to receive milestones upon achievement of development- regulatory & commercial milestones along with royalties on sales of Budesolv in Greater China
  • Luoxin will co-develop Budesolv- a new formulation of the glucocorticoid budesonide in China & will lead the clinical development & obtain the Chinese marketing authorization. Budesolv has completed a P-III clinical study for marketing authorization in the EU
  • Luoxin holds exclusive rights for development- manufacture & commercialize Budesolv in China including mainland- Hong Kong- Macao & Taiwan for allergic rhinitis & is responsible for manufacturing & marketing Budesolv

Click here ­to­ read full press release/ article | Ref: Marino Med | Image: News Medical


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family